Could one HPV shot be enough for kids with HIV? new study investigates

NCT ID NCT04265950

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study looks at children and teens with HIV to find the best number of HPV vaccine doses. Researchers are comparing one, two, or three doses to see if fewer shots can still provide strong protection against HPV. The goal is to simplify vaccination and improve health outcomes for this group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

97 people

The number who actually took part.

Started

Mar 2022

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

9 to 13 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ARMS 1-3: Children must be living with HIV. HIV infection documented by positive molecular test or positive serologic test. * ARM 4: Children must be healthy (e.g., without autoimmune disease or cancer) and not infected with HIV * ARMS 1-3: Children must be on a consistent, clinically appropriate combination antiretroviral therapy (ART) regimen for \> 6 months prior to study enrollment * Children must be 9-13 years-old (at or after 9th birthday, prior to 14th birthday) at enrollment. This will allow vaccination of participants within the recommended age range for receipt of HPV vaccination in Peru and Brazil. Only children ages 9-11 (at or after 9th birthday, prior to 12th birthday) will be enrolled into arms 3 and 4 * Clinical laboratory values for children in Arms 1, 2, \& 3 (CLWH) must be as described below: * CD4% \>15% or CD4 counts \>200 cells/ mm3 * VL (\<400 copies/mL) * All female participants must not be pregnant (all females will receive pregnancy tests at all vaccine visits prior to receipt of study vaccine). The effects of Gardasil 9 on the developing human fetus at the recommended therapeutic dose are unknown. If pregnancy is confirmed during the screening process, enrollment will not occur. If pregnancy occurs after the first vaccine dose, additional vaccine doses will not be administered, but the child will remain in study follow-up. * We anticipate that all children will enter the study prior to sexual debut. Sexual debut will be ascertained by participant questioning in Haiti. Physical examination will not be performed at any of the study sites. Potential participants who report sexual activity will not be enrolled * Children in all arms must have the ability to understand and the willingness to assent to the study. Parents or guardians must be able to understand and willing to sign a written informed consent document Exclusion Criteria: * Children who have a serious illness requiring treatment with systemic medications other than ART (excluding short course oral steroids or inhaled steroid treatment for asthma), are currently under immunomodulatory therapy, received immunosuppressive therapy (\> 10 mg/day of prednisone or equivalent for \> 1 week) in the 6 months prior to enrollment date * Children who received any vaccine within 3 weeks prior to enrollment date (these children will be encouraged to enroll after 3 weeks have passed) * Children who received blood-derived products within 6 months prior to enrollment or planned use during the study period * Children who weigh less than 18 kilograms * Children with cancer being treated with chemotherapy or radiation * Potential participants receiving any other investigational agents may be excluded in the opinion of the supervising physician * Children in all arms with contraindications to vaccination, including pregnancy or breastfeeding * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Children having received HPV vaccination before study entry * Children with evidence of sexually transmitted HIV infection * History of allergic reactions attributed to compounds of similar chemical or biologic composition to HPV vaccination

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV infection are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Evandro Chagas National Institute of Infectious Diseases (INI), Oswaldo Cruz Foundation (FIOCRUZ) STD and AIDS Clinical Research Laboratory

    Rio de Janeiro, Rio de Janeiro, 21040-360, Brazil

  • GHESKIO Center

    Port-au-Prince, Haiti

  • Via Libre

    Lima, 15001, Peru

More trials for these conditions

Other studies related to the condition(s) this trial covers.